朗齊生物醫學股份有限公司 - Section 2
5/5
★
基於 1 評論
朗齊生物醫學股份有限公司 - Launxp.com
本公司目前新藥開發策略是以未被市場所滿足及不易治癒的癌症用藥為優先，除了開發505(b)(1) 新成分新藥外，並進行505(b)(2)新藥研究。
朗齊生物醫學股份有限公司 - Launxp.com
Our strategies focus on developing new chemical entities for cancer and researching a new or better way to benefit patients.
now we obtain several patents for 505(b)(1) and 505(b)(2). Meanwhile, our team is researching the mechanism of anti-proliferation in tumors by repositioning the new indications of FDA-approved drugs which we obtained 505(b)(2) patents already. The results provide advantages of those 505(b)(2) drugs as First-in-class medication in chemotherapy, shortening the development process and saving significant investment. To increase the value and competitiveness of our products, our team is simultaneously developing new antiproliferative drug delivery, such as virus-like nanoparticles and nanoparticles.
now we obtain several patents for 505(b)(1) and 505(b)(2). Meanwhile, our team is researching the mechanism of anti-proliferation in tumors by repositioning the new indications of FDA-approved drugs which we obtained 505(b)(2) patents already. The results provide advantages of those 505(b)(2) drugs as First-in-class medication in chemotherapy, shortening the development process and saving significant investment. To increase the value and competitiveness of our products, our team is simultaneously developing new antiproliferative drug delivery, such as virus-like nanoparticles and nanoparticles.
Contact 朗齊生物醫學股份有限公司
| 地址 ： | 408, Taiwan, Taichung City, Nantun District, Section 2, Gongyi Rd, 51號朗齊生物醫學股份有限公司10樓B1室 |
| 電話 ： | 📞 +889 |
| 網站 ： | http://www.launxp.com/ |
| 分類： |
製藥公司
,
|
| 城市 ： | Gongyi Rd |
|
楊
|
楊德倫 on Google
★ ★ ★ ★ ★ |
Write some of your reviews for the company 朗齊生物醫學股份有限公司
您的評論將非常有助於其他客戶查找和評估信息
Recommend a place for you
